Symmetron

What Symmetron does

Symmetron (legal entity Symmetron Limited, company number 6706234) is a London-based health economics and outcomes research (HEOR) consultancy founded in 2008, employing an estimated 11-50 people. It serves enterprise pharmaceutical, biotechnology, medical device, and medical technology clients, helping them demonstrate product value to health technology assessment (HTA) agencies and payers in order to secure reimbursement and market access. The company reports 45 clients, an average client turnover of $28bn, and that 67% of its work is conducted with clients' global headquarters, indicating a predominantly international, large-enterprise client base.

The company delivers seven interconnected consulting service lines: evidence development (systematic and rapid literature reviews, evidence gap analyses, horizon scanning), health economic modelling (cost-effectiveness models, budget impact models, early-stage and global models with local country adaptations), health technology assessment (reimbursement submissions, value strategy, advisory board management), early evidence strategy, statistical analysis (survival analysis, network meta-analyses, matching-adjusted indirect comparisons), medical writing, and training/workshops. Its technical toolkit centres on statistical evidence synthesis and modelling, with notable components including R Shiny interactive interfaces that make models accessible to non-technical stakeholders and cloud computing infrastructure to accelerate individual patient simulation models. The firm holds specialised expertise across nine therapeutic areas including arthritis and immunology, cardiometabolic health, dermatology, neurology and mental health, oncology, policy and methods, rare diseases, and respiratory.

Symmetron operates a professional-services revenue model: bespoke, project-based consulting engagements sold through consultative, relationship-driven enterprise field sales, supplemented by conference presence (ISPOR Europe), peer-reviewed publications, content marketing, and referral networks. Pricing is not publicly disclosed and is quote-based, tailored to client scope. The firm is privately held with no disclosed parent, institutional investment, or funding rounds, and markets served span the UK, EMEA (Belgium, France, Italy, Switzerland, Sweden, Finland, Slovakia, Ireland, Scotland) and North America (US and Canada).

Name

Symmetron

Legal name

Symmetron Limited

Website

https://symmetron.net

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Symmetron is a London-based health economics and outcomes research (HEOR) consultancy founded in 2008, providing evidence development, health economic modelling, HTA submissions, statistical analysis, and medical writing to enterprise pharmaceutical, biotechnology, and medical device clients seeking reimbursement and market access.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Consulting and Advisory Services: Symmetron generates revenue through professional consulting engagements with pharmaceutical, biotechnology, and medical device companies. Services include evidence development, health economic modelling, HTA submissions, statistical analysis, medical writing, and training. Engagements appear to be project-based and bespoke, with long-term client relationships spanning multiple years and multiple countries.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Symmetron is a health economics and outcomes research (HEOR) consultancy that delivers bespoke consulting services to pharmaceutical, biotechnology, and medical device companies. Its offerings span evidence development (systematic literature reviews, gap analyses), health economic modelling (cost-effectiveness and budget impact models), health technology assessment (reimbursement submissions for HTA agencies), early evidence strategy, statistical analysis (network meta-analyses, survival analyses), medical writing, and training/workshops.

Product overview

Symmetron is an established health economics and outcomes consultancy offering a comprehensive suite of consulting services. The company operates as a single-service consulting firm rather than a platform product, providing seven interconnected service areas: Evidence development (systematic reviews, literature searches), Health economic modelling (cost-effectiveness models, budget impact analyses), Health technology assessment (reimbursement submissions, advisory services), Early evidence strategy (competitive analysis, HTA readiness), Statistical analysis (network meta-analyses, survival analyses), Medical writing (publications, HTA submissions), and Training and workshops. These services work together to help pharmaceutical and medical device companies bring treatments to market by generating and communicating the evidence needed for reimbursement decisions worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Evidence Development Systematic literature reviews, rapid and pragmatic literature reviews, strategic evidence searches, environmental scans, evidence gap analyses, horizon scanning, outcome validation, and stakeholder analysis to support reimbursement submissions and evidence-based decision-making. Targeted at pharmaceutical and medical device companies preparing HTA submissions.
• Health Economic Modelling Cost-effectiveness models, early-stage economic evaluations, global cost-effectiveness models, local country adaptations, budget impact models, model validation, and burden of illness analysis. For pharmaceutical, biotech, and medical device companies seeking HTA-grade economic evidence.
• Health Technology Assessment Reimbursement submissions, advisory board management, value and reimbursement strategies, and rapid delivery of high-quality submissions for HTA bodies. For pharmaceutical, biotech, and medical device clients seeking market access.
• Early Evidence Strategy Competitive landscape analysis, evidence gap analyses, HTA readiness assessments, advisory board management, and economic value quantification to inform early-stage product development decisions. For pharma, biotech, and medical device companies in pre-launch/early development.
• Statistical Analysis Survival analyses, network meta-analyses (indirect treatment comparisons), regression analyses, missing data imputation, propensity score matching, and statistical testing. For pharma, biotech, and medical device clients requiring advanced HEOR statistics.
• Medical Writing Research publications, HTA submissions, white papers, strategy documents, storyboards for product launches, editorial support, and advisory board material development. For pharma, biotech, and medical device clients.
• Training and Workshops Bespoke training sessions, tailored training materials, and online courses covering HEOR techniques, achieving reimbursement, managing HTA projects, and publishing high-impact research. For client internal teams in pharma, biotech, and medical device sectors.

Quantifiable outcome

• 100% client satisfaction — all surveyed clients would hire Symmetron again
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Evidera: PPD/Thermo Fisher-owned HEOR and real-world evidence consultancy delivering evidence synthesis, economic modelling, and HTA support. Closest direct competitor in scope of services, though larger and integrated with broader clinical CRO.
• PRMA Consulting: Specialist market access and HEOR consultancy serving global pharma with HTA submissions, value communications, and economic modelling. Closely matches Symmetron's enterprise pharma client base and HTA-led workflow.
• York Health Economics Consortium: University of York-affiliated HEOR consultancy offering systematic reviews, economic evaluation, and HTA support to pharma and public sector. Similar UK roots, scale, and full-lifecycle HEOR service model as Symmetron.
• RTI Health Solutions: Non-profit-affiliated HEOR consultancy offering systematic reviews, NMAs, cost-effectiveness modelling, and HTA submissions to pharma and medical device clients. Directly comparable to Symmetron's core service portfolio and therapeutic-area breadth.
• Mtech Access: UK-based market access and HEOR consultancy providing HTA submissions, economic modelling, and value communications to pharma. Highly comparable in size, geography, and service mix to Symmetron.
• Source Health Economics: HEOR and market access consultancy providing economic modelling, systematic reviews, and HTA submissions to pharma and medical device clients. Comparable boutique scale and service portfolio.
• Wickenstones: Health economics and market access consultancy specialising in evidence synthesis, NMAs, and HTA submissions. Boutique competitor with overlapping therapeutic-area expertise and client profile.
• Pharmerit (IQVIA): HEOR-focused consultancy now part of IQVIA, providing health economic modelling, RWE, and market access strategy. Direct peer on HEOR deliverables and therapeutic-area coverage, with significantly greater scale.
• Adelphi Values: Health outcomes and value communications consultancy within Adelphi Group, delivering PRO/COA development, HEOR modelling, and HTA submissions. Comparable boutique-scale competitor with similar therapeutic depth.

Emerging players

• Doctor Evidence: Technology-enabled evidence synthesis and RWE platform that complements traditional HEOR consultancies. Adjacent competitor with overlapping methodology (SLR/NMA) but software-platform rather than pure-consulting delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SymmetronHEOR
• LinkedInlinkedin.com/company/symmetron-net

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symmetron